<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>The aim of this study was to evaluate the efficiency and risks of T-cell <z:mpath ids='MPATH_63'>depletion</z:mpath> in prevention of <z:e sem="disease" ids="C0018133" disease_type="Disease or Syndrome" abbrv="GVH">graft versus host disease</z:e> (GVHD) using HLA haploidentical family donors as an alternative source of hematopoietic stem cells (<z:chebi fb="15" ids="50443">HSC</z:chebi>) in children with <z:e sem="disease" ids="C0376545" disease_type="Neoplastic Process" abbrv="">hematological malignancies</z:e> without suitable matched donor </plain></SENT>
<SENT sid="1" pm="."><plain>Ten children, median age 12 years (range, 3-17), were transplanted from haploidentical family donors for <z:hpo ids='HP_0006721'>acute lymphoblastic leukemia</z:hpo> (n = 4), <z:hpo ids='HP_0004808'>acute myelogenous leukemia</z:hpo> (n=2), <z:hpo ids='HP_0005506'>chronic myelogenous leukemia</z:hpo> (n = 2), non-Hodgkin <z:hpo ids='HP_0002665'>lymphoma</z:hpo> (n = 1) and <z:hpo ids='HP_0002863'>myelodysplastic syndrome</z:hpo> (n = 1) </plain></SENT>
<SENT sid="2" pm="."><plain>Parents were donors for nine, sibling for one patient </plain></SENT>
<SENT sid="3" pm="."><plain>T-cell <z:mpath ids='MPATH_63'>depletion</z:mpath> of <z:chebi fb="15" ids="50443">HSC</z:chebi> was performed using CellPro followed by antiCD2/CD3 <z:mpath ids='MPATH_63'>depletion</z:mpath> in 7, and CliniMacs magnetic sorting in 3 grafts </plain></SENT>
<SENT sid="4" pm="."><plain>Primary engraftment was achieved in nine patients </plain></SENT>
<SENT sid="5" pm="."><plain>Patient with graft failure was successfully re-grafted </plain></SENT>
<SENT sid="6" pm="."><plain>Primary <z:hpo ids='HP_0011009'>acute</z:hpo> GVHD was diagnosed in one patient who got higher amount of T-cells in the graft </plain></SENT>
<SENT sid="7" pm="."><plain>Secondary GVHD was induced by add-backs of lymphocytes in four patients </plain></SENT>
<SENT sid="8" pm="."><plain>Three patients developed <z:hpo ids='HP_0011010'>chronic</z:hpo> GVHD </plain></SENT>
<SENT sid="9" pm="."><plain>Four patients died due to transplant related mortality (40%), one from <z:e sem="disease" ids="C0948441" disease_type="Disease or Syndrome" abbrv="VOD">veno-occlusive disease</z:e>, two due to CMV <z:hpo ids='HP_0002090'>pneumonia</z:hpo> and one of <z:e sem="disease" ids="C0004030" disease_type="Disease or Syndrome" abbrv="">aspergillosis</z:e> with extensive <z:hpo ids='HP_0011010'>chronic</z:hpo> GVHD </plain></SENT>
<SENT sid="10" pm="."><plain>Four patients relapsed with <z:hpo ids='HP_0001909'>leukemia</z:hpo> within 35-98 days post transplant, three without previous signs of GVHD, and <z:hpo ids='HP_0000001'>all</z:hpo> died </plain></SENT>
<SENT sid="11" pm="."><plain>Two patients are alive and well 26 and 42 months after transplant </plain></SENT>
<SENT sid="12" pm="."><plain>Haploidentical family donors appear to be a reasonable alternative option for patients with urgent indications for allogeneic transplant and/or without a matched donor </plain></SENT>
</text></document>